Sutro Net Interest Income from 2010 to 2026
| STRO Stock | USD 14.89 0.06 0.40% |
Net Interest Income | First Reported 2019-03-31 | Previous Quarter -8.2 M | Current Value -8.4 M | Quarterly Volatility 5.1 M |
Check Sutro Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sutro Biopharma's main balance sheet or income statement drivers, such as Net Interest Income of 16.1 M, Interest Income of 53.6 M or Depreciation And Amortization of 6.3 M, as well as many indicators such as Price To Sales Ratio of 1.95, Dividend Yield of 0.0 or PTB Ratio of 3.0. Sutro financial statements analysis is a perfect complement when working with Sutro Biopharma Valuation or Volatility modules.
Sutro | Net Interest Income | Build AI portfolio with Sutro Stock |
Evaluating Sutro Biopharma's Net Interest Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Sutro Biopharma's fundamental strength.
Latest Sutro Biopharma's Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Sutro Biopharma over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Sutro Biopharma's Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sutro Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Sutro Net Interest Income Regression Statistics
| Arithmetic Mean | 2,532,907 | |
| Coefficient Of Variation | 241.88 | |
| Mean Deviation | 4,562,563 | |
| Median | 251,000 | |
| Standard Deviation | 6,126,674 | |
| Sample Variance | 37.5T | |
| Range | 18.7M | |
| R-Value | 0.58 | |
| Mean Square Error | 26.4T | |
| R-Squared | 0.34 | |
| Significance | 0.01 | |
| Slope | 707,520 | |
| Total Sum of Squares | 600.6T |
Sutro Net Interest Income History
About Sutro Biopharma Financial Statements
Sutro Biopharma investors utilize fundamental indicators, such as Net Interest Income, to predict how Sutro Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 15.4 M | 16.1 M |
Pair Trading with Sutro Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Sutro Stock
Moving against Sutro Stock
| 0.92 | ABP | Abpro Holdings | PairCorr |
| 0.85 | KURA | Kura Oncology | PairCorr |
| 0.83 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.67 | LYRA | Lyra Therapeutics | PairCorr |
| 0.6 | GNLX | Genelux Common | PairCorr |
The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.
The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Sutro Biopharma Correlation against competitors. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Will Biotechnology sector continue expanding? Could Sutro diversify its offerings? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sutro Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.60) | Revenue Per Share | Quarterly Revenue Growth 0.138 | Return On Assets | Return On Equity |
Understanding Sutro Biopharma requires distinguishing between market price and book value, where the latter reflects Sutro's accounting equity. The concept of intrinsic value - what Sutro Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Sutro Biopharma's price substantially above or below its fundamental value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sutro Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.